DOCSLIB.ORG

IIIHIIIHIIII O USOO5357636A United States Patent (19) [11] Patent Number: 5,357,636 Dresdner, Jr

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
IIIHIIIHIIII O USOO5357636A United States Patent (19) [11] Patent Number: 5,357,636 Dresdner, Jr IIIHIIIHIIII O USOO5357636A United States Patent (19) [11] Patent Number: 5,357,636 Dresdner, Jr. et al. (45) Date of Patent: Oct. 25, 1994 54 FLEXIBLE PROTECTIVE MEDICAL sis', 1976, New England Journal of Medicine, 294(3): GLOVES AND METHODS FORTHER USE pp. 1286-1287. 76 Inventors: Karl P. Dresdn O Viljanto, "Disinfection of Surgical Wounds Without 76) St., Apt. its. 3:...ith Inhibition of Normal Wound Healing', 1980, Arch., N.Y. 10036; Kenneth H. Dangman, Surg, 115, pp. 253–256. 400 Riverside Dr., Apt. #1A, New Rodeheaver, et al., "Bactericidal Activity and Toxicity York City, N.Y. 10032; Edward A. of Iodine-Containing Solutions in Wounds', 1982, Jazlowiecki, 15 Sachems Trail, west Arch. Surg, 117, pp. 181-186. Simsbury, Conn. 06092 (List continued on next page.) 212 Appl ... No.:NO. 906,829 Primary Examiner-Clifford D. Crowder 22 Filed: Jun. 30, 1992 Assistant Examiner-Amy B. Vanatta 51) Int. Cl. ............... A41D 13/10; A41D 19/00 57 ABSTRACT 52 U.S.C. ......................................... 2/1617; 2/167; (57) 2/168; 2/169 A flexible protective medical glove containing a non 58) Field of Search ............... 2/161 R, 168, 167, 169, liquid antiseptic composition and methods for its use are 2/164, 159, 1616, 1617, 1618, 16, 21; 128/292, disclosed. The glove comprises a thin inner layer and a 306, 307, 842, 844; 604/349; 427/2 thin outer layer of material; preferably the outer layer is a more elastic and less plastic layer than the inner layer. 56) References Cited A compartment between the layers of the glove is capa U.S. PATENT DOCUMENTS ble of providing a non-liquid antiseptic composition 2,541,103 2/1951 Sander . which comprises an antiseptic in a non-liquid composi 3,633,216 1/1972 Shonholtz ............................... 2/168 tion. The non-liquid antiseptic composition may also 4,526,828 7/1985 Fogt et al. contain a surface-active agent, an algesic agent, a color 4,771,482S. 9/198823 SEM"Shlenker Poo-oooowoon a an oppos 2/161R ant,modifying a vasoconstrictive agent. An object agent, puncturing an odorant, the or aglove viscosity wall 4,935,260 6/1990 Shlenker ............................. is can become coated with the non-liquid antiseptic com 5,003,628 4/1991 Miyake et al. position and can automatically transfer some of the 5,019,604 5/1991 Lemole . antiseptic composition from the glove onto the hand 5,024,852 6/1991 Busnel et al. ................... 2/161 RX and into a hand wound should the object cause a 5,031,245 7/1991 Milner . wound; useful as an immediate preventative antiseptic 5,045,341 9/1991 Shlenker ............................. 2/922 treatment to help to decontaminate the hand and hand 5,128,168 7/1992 Shenker et a wound of infectious pathogens that may have been 5,130,159 7/1992 Shlenker et al. ................... 2/167 X transferred there by the object. The treatment can help FOREIGN PATENT DOCUMENTS to protect a gloved individual such as a surgeon, a medi WO91/10409 7/1991 PCT Int'l Appl. cal doctor, a health care worker, a law enforcement 9014048 11/1990 World Int. Prop. O................ 2/21 officer, a dentist or any worker whose work may place them at some risk of becoming contaminated through OTHER PUBLICATIONS the hands by an infectious pathogen including the Stecher, et al., "Nonoxynol”, 1968 8th ed., The Merck AIDS virus or hepatitis B virus. Index, p. 745. Maki, "Lister Revisted: Surgical Antisepsis and Asep- 20 Claims, 7 Drawing Sheets 5,357,636 Page 2 OTHER PUBLICATIONS tients with Human Immunodeficiency Virus', 1990, Surgery-Gynecology & Obstetrics, vol. 171, No. 2, Simmons, et al., “CDC Guidelines for the Prevention pp. 99-106. and Control of Nosocomial Infections' (Guideline for Henderson, et al., “Risk of Occupational Transmission hospital environmental control), Am. Journal of Infec of Human Immunodeficiency Virus Type 1 (HIV-1) tion Control, 1983, 113), pp. 91-120. Associated with Clinical Exposures', 1990, Annals of Simmons, et al., “CDC Guidelines for the Prevention Internal Medicine, vol. 113, pp. 740–746. and Control of Nosocomial Infections' (Guideline for Beekmann, et al., "Risky Business: Using Necessarily prevention of surgical wound infections), Am. Journal Imprecise Casualty Counts to Estimate Occupational Risks for HIV-1 Infection', 1990, Infection Control of Infection Control, 1983, 114), pp. 133-143. Hospital Epidemiology, 117, pp. 371-379. Hicks, et al., “Inactivation of HTLV-III/Lav-Infected Bloomfield, et al., "Evaluation of Hypochlorite-Releas Cultures or Normal Human Lymphocytes. By Nonox ing Disinfectants Against the Human Immunodefi ynol-9 in Vitro', 1985, Dec. 21/28, The Lancet, pp. ciency Virus (HIV)', 1990, Journal of Hospital Infec 422-1423. tion, 15, pp. 273-278. Harvey, "Antiseptics and Disinfectants; Fungicides; Johnson, et al., “Efficacy of Glove Combinations in Ectoparasiticides', 1985, In: The Pharmacological Reducing Cell Culture Infection. After Glove Puncture Basis of Therapeutics; 7th ed., Chapter 41, pp. 959-979. With Needles Contaminated With Human Immunodefi Weiss, et al., “HTLV-III Infection Among Health Care ciency Virus Type 1", 1991, Infection Control and Hos Workers', 1985; The Journal of the Am. Med. Assoc., pital Epidemiology, 127, pp. 435-438. vol. 254, No. 15; pp. 2089-2093. Panlilio, et al., "Blood Contacts During Surgical Proce Rietmeijer et al., “Condoms as Physical and Chemical dures', 1991, Journal of American Medical Association, Barriers Against Human Immunodeficiency Virus,” 265(12), pp. 1533-1537. 1988, The Journal of the Am. Med. Assoc., 295.12, pp. Gross, "Many Doctors Infected with AIDS Don't Fol 1851-1853. low New U.S. Guidelines', 1991, The New York Newsom, et al., “What is in the Surgeon’s Glove?', Times, vol. CXL. No. 48, 696, p. 1. 1988, Journal of Hospital Infection, 11supplement A), Orentlicher, “HIV-Infected Surgeons: Behringer v. pp. 244-259. Medical Center', 1991, The Journal of American Medi Bartlett, “Testing for HIV Infection: Recommendations cal Associations, 2668), pp. 1134-1137. for Surgeons', 1988, Am. College of Surgeons Bulletin, Zanowiak, "Skin Infections: The Role of OTC Ther 733), pp. 4-10. apy”, Jun. 1991, U.S. Pharmacist pp. 40-47. Gerberding, et al., “Risk of Exposure of Surgical Per Mast, "Factors Predicting Infectivity Following Need sonnel to Patients’ Blood During Surgery at San Fran lestick Exposure to HIV: A Invitro Model”, 1991, Clin cisco General Hospital', 1990, The New England Jour ical Research, 39(1): p. 58A. nal of Medicine, 322(25) pp. 1788-1793. Wright, "Mechanisms of Glove Tears and Sharp Inju Montefiori, et al., “Effective Inactivation of Human ries Among Surgical Personnel,' 1991, Journal of Immunodeficiency Virus With Chlorhexidine Antisep American Medicical Association, 266(12): 1668-1671. tics Containing Detergents and Alcohol', 1990, Journal Boscia, Peterson, Szpalski, Panlilio & Gerberding, Let of Hospital Infection, 15, pp. 279-282. ters to the Editor: “Surgery, AIDS, and Hepatitus B', Speller, et al., “Acquired Immune Deficiency Syn 1991, Journal of American Medical Association, 266(10: drome: Recommendations of a Working Party of the 1360-1362. Hospital Infection Society”, 1990, Journal of Hospital Belkin, L. "Fear of Disease Changing How Doctors Infection, 15 pp. 7-34. Work”, Apr. 7, 1992, A1, B2, New York Times. Sanders, et al., "Outer Gloves in Orthopaedic Proce Assoc. Press, "Teen-Agers and AIDS: The Risk Wors dure', 1990, The Journal of Bone and Joint Surgery, ens”, Apr. 14, 1992, C3, New York Times-Medical Inc., 72-A6, pp. 914-917. Science Section. Closs & Tierney, “Theatre Gowns: A Survey of the Remington's Pharmaceutical Sciences: 1965, "Suspen Extent of User Protection', 1990, Journal of Hospital sions', pp. 455-459; Medicated Applications pp. Infection, 15, pp. 375-378. 525-556; Antimicrobial Drugs, pp. 1228-1252. Mandlebort, et al., “A Survey of Exposure, Practices Remington's Pharmaceutical Sciences: 1990, "Antimi and Recommendations of Surgeons in the Care of Pa crobial Drugs', pp. 1163-1241. U.S. Patent Oct. 25, 1994 Sheet 1 of 7 5,357,636 FIG. 1A U.S. Patent Oct. 25, 1994 Sheet 2 of 7 5,357,636 F.G. 1B U.S. Patent Oct. 25, 1994 Sheet 3 of 7 5,357,636 U.S. Patent Oct. 25, 1994 Sheet 4 of 7 5,357,636 FIG. 2B U.S. Patent Oct. 25, 1994 Sheet 5 of 7 5,357,636 FIG. 2C U.S. Patent Oct. 25, 1994 Sheet 6 of 7 5,357,636 FG. 3 U.S. Patent Oct. 25, 1994 Sheet 7 of 7 5,357,636 FG. 4 5,357,636 1. 2 to a surface of a surgical wound from a surgeon's hands. FLEXIBLE PROTECTIVE MEDICAL GLOVES Nonsterile latex medical gloves are also known in the AND METHODS FOR THEIR USE field as examination gloves; they are used during non sterile procedures; are made available usually in a size FIELD OF THE INVENTION that can suitably fit either hand and are often packaged The present invention is a flexible protective medical in bulk, for example in quanities of 50 per box. Non-ster glove that relates to the thin-walled medical glove that ile procedures include the medical examination of doctors, health care workers and other workers can human body surfaces, body invaginations and body wear on one or both hands as a physical barrier form of orifices; nonsterile medical gloves are also worn for protection. In particular the present invention is a glove 10 protecting the hands of medical, research or hospital containing an antiseptic composition other than a liquid workers from contact with hazardous substances and antiseptic composition within the glove wall;:the non surfaces. Examples of hazardous substances and Sur liquid antiseptic composition comprises an antiseptic in faces include but are not limited to the following exam a non-liquid composition; for example, the composition ples: biological waste products such as feces and urine, may comprise a powder, a paste, a foam, a gel, a coat 15 soiled wound dressings, garments or other materials, ing, a solid layer, a semi-solid foam, a putty or a state of syringe needles, other medical devices, irritating or matter that lacks the ability to flow like a liquid.
Load more

Recommended publications
  • Antiseptics and Disinfectants for the Treatment Of
    Verstraelen et al. BMC Infectious Diseases 2012, 12:148 http://www.biomedcentral.com/1471-2334/12/148 RESEARCH ARTICLE Open Access Antiseptics and disinfectants for the treatment of bacterial vaginosis: A systematic review Hans Verstraelen1*, Rita Verhelst2, Kristien Roelens1 and Marleen Temmerman1,2 Abstract Background: The study objective was to assess the available data on efficacy and tolerability of antiseptics and disinfectants in treating bacterial vaginosis (BV). Methods: A systematic search was conducted by consulting PubMed (1966-2010), CINAHL (1982-2010), IPA (1970- 2010), and the Cochrane CENTRAL databases. Clinical trials were searched for by the generic names of all antiseptics and disinfectants listed in the Anatomical Therapeutic Chemical (ATC) Classification System under the code D08A. Clinical trials were considered eligible if the efficacy of antiseptics and disinfectants in the treatment of BV was assessed in comparison to placebo or standard antibiotic treatment with metronidazole or clindamycin and if diagnosis of BV relied on standard criteria such as Amsel’s and Nugent’s criteria. Results: A total of 262 articles were found, of which 15 reports on clinical trials were assessed. Of these, four randomised controlled trials (RCTs) were withheld from analysis. Reasons for exclusion were primarily the lack of standard criteria to diagnose BV or to assess cure, and control treatment not involving placebo or standard antibiotic treatment. Risk of bias for the included studies was assessed with the Cochrane Collaboration’s tool for assessing risk of bias. Three studies showed non-inferiority of chlorhexidine and polyhexamethylene biguanide compared to metronidazole or clindamycin. One RCT found that a single vaginal douche with hydrogen peroxide was slightly, though significantly less effective than a single oral dose of metronidazole.
    [Show full text]
  • Sterilization and Disinfection
    Sterilization and Disinfection Sterilization is defined as the process where all the living microorganisms, including bacterial spores are killed. Sterilization can be achieved by physical, chemical and physiochemical means. Chemicals used as sterilizing agents are called chemisterilants. Disinfection is the process of elimination of most pathogenic microorganisms (excluding bacterial spores) on inanimate objects. Disinfection can be achieved by physical or chemical methods. Chemicals used in disinfection are called disinfectants. Different disinfectants have different target ranges, not all disinfectants can kill all microorganisms. Some methods of disinfection such as filtration do not kill bacteria, they separate them out. Sterilization is an absolute condition while disinfection is not. The two are not synonymous. Decontamination is the process of removal of contaminating pathogenic microorganisms from the articles by a process of sterilization or disinfection. It is the use of physical or chemical means to remove, inactivate, or destroy living organisms on a surface so that the organisms are no longer infectious. Sanitization is the process of chemical or mechanical cleansing, applicable in public health systems. Usually used by the food industry. It reduces microbes on eating utensils to safe, acceptable levels for public health. Asepsis is the employment of techniques (such as usage of gloves, air filters, uv rays etc) to achieve microbe-free environment. Antisepsis is the use of chemicals (antiseptics) to make skin or mucus membranes devoid of pathogenic microorganisms. Bacteriostasis is a condition where the multiplication of the bacteria is inhibited without killing them. Bactericidal is that chemical that can kill or inactivate bacteria. Such chemicals may be called variously depending on the spectrum of activity, such as bactericidal, virucidal, fungicidal, microbicidal, sporicidal, tuberculocidal or germicidal.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • Alcohol ⊗ Hypoglycaemia, and Hypokalaemia May Occur
    Acridine Derivatives/Alcohol 1625 Acriflavinium Chloride (rINN) Pharmacopoeias. Chin., Eur. (see p.vii), and Jpn describe the Booze; Drinks; Grog; Juice; Jungle juice; Liq; Liquor; Lunch head; Moonshine; Piss; Sauce; Schwillins. Acriflavine; Acriflavine Hydrochloride; Acriflavinii Chloridum; monohydrate. Ph. Eur. 6.2 (Ethacridine Lactate Monohydrate). A yellow crys- Acriflavinii Dichloridum; Acriflavinium, Chlorure d’; Akriflavinium- Pharmacopoeias. Various strengths are included in Br., Chin., talline powder. Sparingly soluble in water; very slightly soluble chlorid; Cloruro de acriflavinio. A mixture of 3,6-diamino-10- Eur. (see p.vii), Int., Jpn, US, and Viet. Also in USNF. in alcohol; practically insoluble in dichloromethane. A 2% solu- In Martindale the term alcohol is used for alcohol 95 or 96% v/v. methylacridinium chloride hydrochloride and 3,6-diaminoacrid- tion in water has a pH of 5.5 to 7.0. Protect from light. ine dihydrochloride. Ph. Eur. 6.2 (Ethanol, Anhydrous; Ethanolum Anhydricum; Etha- nol BP 2008). It contains not less than 99.5% v/v or 99.2% w/w Акрифлавиния Хлорид Proflavine Hemisulfate of C2H5OH at 20°. A colourless, clear, volatile, flammable, hy- CAS — 8063-24-9; 65589-70-0. Proflavine Hemisulphate (pINNM); Hemisulfato de proflavina; groscopic liquid; it burns with a blue, smokeless flame. B.p. ATC — R02AA13. Neutral Proflavine Sulphate; Proflavine, Hémisulfate de; Proflavini about 78°. Miscible with water and with dichloromethane. Pro- ATC Vet — QG01AC90; QR02AA13. Hemisulfas. 3,6-Diaminoacridine sulphate dihydrate. tect from light. The BP 2008 gives Absolute Alcohol and Dehydrated Alcohol Профлавина Гемисульфат as approved synonyms. (C13H11N3)2,H2SO4,2H2O = 552.6. Ph. Eur. 6.2 (Ethanol (96 per cent)).
    [Show full text]
  • Chapter-Vi Difectants
    R.KAVITHA, M.PHARM, LECTURER, DEPARTMENT OF PHARMACEUTICS, SRM COLLEGE OF PHARMACY, SRM UNIVERSITY, KATTANKULATHUR. CHEMICAL METHODS OF DISINFECTION: Disinfectants are those chemicals that destroy pathogenic bacteria from inanimate surfaces. Some chemical have very narrow spectrum of activity and some have very wide. Those chemicals that can sterilize are called chemisterilants. Those chemicals that can be safely applied over skin and mucus membranes are called antiseptics. Classification of disinfectants: 1. Based on consistency a. Liquid (E.g., Alcohols, Phenols) b. Gaseous (Formaldehyde vapour, Ethylene oxide) 2. Based on spectrum of activity a. High level b. Intermediate level c. Low level 3. Based on mechanism of action a. Action on membrane (E.g., Alcohol, detergent) b. Denaturation of cellular proteins (E.g., Alcohol, Phenol) c. Oxidation of essential sulphydryl groups of enzymes (E.g., H2O2, Halogens) d. Alkylation of amino-, carboxyl- and hydroxyl group (E.g., Ethylene Oxide, Formaldehyde) e. Damage to nucleic acids (Ethylene Oxide, Formaldehyde) ALCOHOLS: Mode of action: Alcohols dehydrate cells, disrupt membranes and cause coagulation of protein. Examples: Ethyl alcohol, isopropyl alcohol and methyl alcohol Application: A 70% aqueous solution is more effective at killing microbes than absolute alcohols. 70% ethyl alcohol (spirit) is used as antiseptic on skin. Isopropyl alcohol is preferred to ethanol. It can also be used to disinfect surfaces. It is used to disinfect clinical thermometers. Methyl alcohol kills fungal spores, hence is useful in disinfecting inoculation hoods. Disadvantages: Skin irritant, volatile (evaporates rapidly), inflammable ALDEHYDES: Mode of action: Acts through alkylation of amino-, carboxyl- or hydroxyl group, and probably damages nucleic acids.
    [Show full text]
  • Alphabetical Listing of ATC Drugs & Codes
    Alphabetical Listing of ATC drugs & codes. Introduction This file is an alphabetical listing of ATC codes as supplied to us in November 1999. It is supplied free as a service to those who care about good medicine use by mSupply support. To get an overview of the ATC system, use the “ATC categories.pdf” document also alvailable from www.msupply.org.nz Thanks to the WHO collaborating centre for Drug Statistics & Methodology, Norway, for supplying the raw data. I have intentionally supplied these files as PDFs so that they are not quite so easily manipulated and redistributed. I am told there is no copyright on the files, but it still seems polite to ask before using other people’s work, so please contact <[email protected]> for permission before asking us for text files. mSupply support also distributes mSupply software for inventory control, which has an inbuilt system for reporting on medicine usage using the ATC system You can download a full working version from www.msupply.org.nz Craig Drown, mSupply Support <[email protected]> April 2000 A (2-benzhydryloxyethyl)diethyl-methylammonium iodide A03AB16 0.3 g O 2-(4-chlorphenoxy)-ethanol D01AE06 4-dimethylaminophenol V03AB27 Abciximab B01AC13 25 mg P Absorbable gelatin sponge B02BC01 Acadesine C01EB13 Acamprosate V03AA03 2 g O Acarbose A10BF01 0.3 g O Acebutolol C07AB04 0.4 g O,P Acebutolol and thiazides C07BB04 Aceclidine S01EB08 Aceclidine, combinations S01EB58 Aceclofenac M01AB16 0.2 g O Acefylline piperazine R03DA09 Acemetacin M01AB11 Acenocoumarol B01AA07 5 mg O Acepromazine N05AA04
    [Show full text]
  • RECENT DEVELOPMENTS in WOUND ANTISEPTICS by H
    Postgrad Med J: first published as 10.1136/pgmj.22.246.118 on 1 April 1946. Downloaded from 118 POST-GRADUATE MEDICAL JOURNAL April, I946 If the patient is allowed fluid by mouth, it 4. If the apparatus does not appear to be work- should be given by the feeder between times of ing, the clips should be clamped, the appa- aspiration. ratus disconnected from the gastric tube and Aspiration is performed at regular intervals some water injected down the tube to make either every hour or half-hour according to sure that it is patent. instructions. The aspirated material must always be saved The Time for Removal of the Tube: The tube is for inspection. removed under the Doctor's instructions. In 2. Continuous Suction: A study of the diagram cases of intestinal obstruction this is usually (Fig. 2) will explain the work of the apparatus, after the patient has had one bowel action, and and attention must be to the has passed flatus on at least two occasions. particular paid After operations on the stomach, the tube is following points:- removed when the aspirated contents appear I. The reservoir A must never be allowed to clear contain bile. become empty. and 2. The end of the tubing in bottle B must be Vomiting: If a patient who is undergoing gastro- below the level of the water. intestinal suction vomits, it indicates that there 3. The clips D and E must be clamped before is some fault in the procedure, and is a reflection and during the changing of the bottles A and on the management of the suction.
    [Show full text]
  • Comparative Efficacy of Three Antiseptics As Surgical Skin Preparations in Dogs
    COMPARATIVE EFFICACY OF THREE ANTISEPTICS AS SURGICAL SKIN PREPARATIONS IN DOGS by Charles Boucher Submitted in partial fulfilment of the requirements for the degree of MMedVet (Surgery)(Small Animals) Companion Animal Clinical Studies Faculty of Veterinary Science University of Pretoria Pretoria, April 2017 Dissertation Comparative efficacy of three antiseptics as surgical skin preparations in dogs Charles Boucher 97099245 Supervisor: Prof Marthinus J. Hartman Co-supervisor: Dr Maryke M. Henton Department: Companion Animal Clinical Studies Faculty of Veterinary Science University: University of Pretoria DECLARATION I, Charles Boucher, student number 97099245 hereby declare that this dissertation, “Comparative efficacy of three antiseptics as surgical skin preparations in dogs”, is submitted in accordance with the requirements for the Master in Veterinary Medicine degree at University of Pretoria, is my own original work and has not previously been submitted to any other institution of higher learning. All sources cited or quoted in this research paper are indicated and acknowledged with a comprehensive list of references. Signature: ____________________ Dr Charles Boucher Date: 31 March 2017 i DEDICATION I dedicate this research to my loving wife, Christie, and our two children Charlie and Celeste, for their unconditional love and support in my pursuit of a lifelong dream. Quote by Sir Thomas Clifford Allbutt, about Lord Joseph Lister (English surgeon, medical scientist and pioneer of aseptic surgery): “Lister saw the vast importance of the discoveries of Pasteur. He saw it because he was watching on the heights, and he was watching there alone.” ii ACKNOWLEDGEMENTS My sincere appreciation and grateful thanks to the following people for their contributions in helping me to complete this research project: Professor Marthinus Hartman, acted as my research supervisor.
    [Show full text]
  • Method of Treating a Fabric
    (19) TZZ¥ZZ _T (11) EP 3 088 502 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 02.11.2016 Bulletin 2016/44 C11D 3/386 (2006.01) (21) Application number: 16167242.3 (22) Date of filing: 27.04.2016 (84) Designated Contracting States: (72) Inventors: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB • LANT, Neil Joseph GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO Newcastle upon Tyne, NE12 9TS (GB) PL PT RO RS SE SI SK SM TR • WOOD, Rebecca Louise Designated Extension States: Newcastle upon Tyne, NE12 9TS (GB) BA ME • GUMMEL, Jeremie Robert Marcel Designated Validation States: Newcastle upon Tyne, NE12 9TS (GB) MA MD (74) Representative: Peet, Jillian Wendy (30) Priority: 29.04.2015 EP 15165814 Procter & Gamble Technical Centres Limited 15.10.2015 EP 15190045 Whitley Road Longbenton (71) Applicant: The Procter & Gamble Company Newcastle upon Tyne Cincinnati, OH 45202 (US) NE12 9TS (GB) (54) METHOD OF TREATING A FABRIC (57) Method for treating a hydrophobically-modified textile with an aqueous solution of a nuclease enzyme, preferably a deoxyribonuclease or ribonuclease enzyme, rinsing and drying the textile. Use of the finishing step for improved cleaning with an aqueous solution of a nuclease enzyme, preferably a deoxyribonuclease or ribonuclease enzyme EP 3 088 502 A1 Printed by Jouve, 75001 PARIS (FR) EP 3 088 502 A1 Description FIELD OF INVENTION 5 [0001] This invention relates to methods of treating textile surfaces. BACKGROUND OF THE INVENTION [0002] Fabric whiteness is a constant challenge for laundry detergent manufacturers.
    [Show full text]
  • Pharmaceuticals (Monocomponent Products) ………………………..………… 31 Pharmaceuticals (Combination and Group Products) ………………….……
    DESA The Department of Economic and Social Affairs of the United Nations Secretariat is a vital interface between global and policies in the economic, social and environmental spheres and national action. The Department works in three main interlinked areas: (i) it compiles, generates and analyses a wide range of economic, social and environmental data and information on which States Members of the United Nations draw to review common problems and to take stock of policy options; (ii) it facilitates the negotiations of Member States in many intergovernmental bodies on joint courses of action to address ongoing or emerging global challenges; and (iii) it advises interested Governments on the ways and means of translating policy frameworks developed in United Nations conferences and summits into programmes at the country level and, through technical assistance, helps build national capacities. Note Symbols of United Nations documents are composed of the capital letters combined with figures. Mention of such a symbol indicates a reference to a United Nations document. Applications for the right to reproduce this work or parts thereof are welcomed and should be sent to the Secretary, United Nations Publications Board, United Nations Headquarters, New York, NY 10017, United States of America. Governments and governmental institutions may reproduce this work or parts thereof without permission, but are requested to inform the United Nations of such reproduction. UNITED NATIONS PUBLICATION Copyright @ United Nations, 2005 All rights reserved TABLE OF CONTENTS Introduction …………………………………………………………..……..……..….. 4 Alphabetical Listing of products ……..………………………………..….….…..….... 8 Classified Listing of products ………………………………………………………… 20 List of codes for countries, territories and areas ………………………...…….……… 30 PART I. REGULATORY INFORMATION Pharmaceuticals (monocomponent products) ………………………..………… 31 Pharmaceuticals (combination and group products) ………………….……........
    [Show full text]
  • Www .Alfa.Com
    Bio 2013-14 Alfa Aesar North America Alfa Aesar Korea Uni-Onward (International Sales Headquarters) 101-3701, Lotte Castle President 3F-2 93 Wenhau 1st Rd, Sec 1, 26 Parkridge Road O-Dong Linkou Shiang 244, Taipei County Ward Hill, MA 01835 USA 467, Gongduk-Dong, Mapo-Gu Taiwan Tel: 1-800-343-0660 or 1-978-521-6300 Seoul, 121-805, Korea Tel: 886-2-2600-0611 Fax: 1-978-521-6350 Tel: +82-2-3140-6000 Fax: 886-2-2600-0654 Email: [email protected] Fax: +82-2-3140-6002 Email: [email protected] Email: [email protected] Alfa Aesar United Kingdom Echo Chemical Co. Ltd Shore Road Alfa Aesar India 16, Gongyeh Rd, Lu-Chu Li Port of Heysham Industrial Park (Johnson Matthey Chemicals India Toufen, 351, Miaoli Heysham LA3 2XY Pvt. Ltd.) Taiwan England Kandlakoya Village Tel: 866-37-629988 Bio Chemicals for Life Tel: 0800-801812 or +44 (0)1524 850506 Medchal Mandal Email: [email protected] www.alfa.com Fax: +44 (0)1524 850608 R R District Email: [email protected] Hyderabad - 501401 Andhra Pradesh, India Including: Alfa Aesar Germany Tel: +91 40 6730 1234 Postbox 11 07 65 Fax: +91 40 6730 1230 Amino Acids and Derivatives 76057 Karlsruhe Email: [email protected] Buffers Germany Tel: 800 4566 4566 or Distributed By: Click Chemistry Reagents +49 (0)721 84007 280 Electrophoresis Reagents Fax: +49 (0)721 84007 300 Hydrus Chemical Inc. Email: [email protected] Uchikanda 3-Chome, Chiyoda-Ku Signal Transduction Reagents Tokyo 101-0047 Western Blot and ELISA Reagents Alfa Aesar France Japan 2 allée d’Oslo Tel: 03(3258)5031 ...and much more 67300 Schiltigheim Fax: 03(3258)6535 France Email: [email protected] Tel: 0800 03 51 47 or +33 (0)3 8862 2690 Fax: 0800 10 20 67 or OOO “REAKOR” +33 (0)3 8862 6864 Nagorny Proezd, 7 Email: [email protected] 117 105 Moscow Russia Alfa Aesar China Tel: +7 495 640 3427 Room 1509 Fax: +7 495 640 3427 ext 6 CBD International Building Email: [email protected] No.
    [Show full text]
  • Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös
    LUONNOS 5.12.2018 Lääkealan turvallisuus- ja kehittämiskeskuksen päätös N:o xxxx lääkeluettelosta Annettu Helsingissä 15. päivänä maaliskuuta 2019 ————— Lääkealan turvallisuus- ja kehittämiskeskus on 10 päivänä huhtikuuta 1987 annetun lääke- lain (395/1987) 83 §:n nojalla päättänyt vahvistaa seuraavan lääkeluettelon: 1 § vallisten valmisteiden ja erityislupavalmis- Luettelon tarkoitus teiden vaikuttavia lääkeaineita. Liitteessä 1 on lueteltu ainoastaan lääkeai- Tämä päätös sisältää luettelon Suomessa neet. Lääkeaineiden suoloja ja estereitä ei ole lääkkeellisessä käytössä olevista aineista ja lueteltu. Lääkeaineet ovat valmisteessa suo- rohdoksista. Lääkeluettelo laaditaan ottaen lamuodossa teknisen käsiteltävyyden vuoksi. huomioon lääkelain 3 §:n ja 5 §:n säännök- Lääkeaine ja sen suolamuoto ovat biologises- set. ti samanarvoisia. Lääkkeellä tarkoitetaan valmistetta tai ai- Liitteen 1 A aineet ovat lääkeaineanalogeja netta, jonka tarkoituksena on sisäisesti tai ja prohormoneja. Kaikki liitteen 1 A aineet ulkoisesti käytettynä parantaa, lievittää tai rinnastetaan aina vaikutuksen perusteella ehkäistä sairautta tai sen oireita ihmisessä tai ainoastaan lääkemääräyksellä toimitettaviin eläimessä. Lääkkeeksi katsotaan myös sisäi- lääkkeisiin. sesti tai ulkoisesti käytettävä aine tai aineiden yhdistelmä, jota voidaan käyttää ihmisen tai 2 § eläimen elintoimintojen palauttamiseksi, Lääkkeitä ovat korjaamiseksi tai muuttamiseksi farmakolo- 1) tämän päätöksen liitteessä 1 luetellut ai- gisen, immunologisen tai metabolisen vaiku- neet, niiden suolat
    [Show full text]